ResearcherTianjin Medical University Cancer Institute and HospitalActive in the last 2 years

Ting Deng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5477-7972; OpenAlex author ID A5100682726. Sources: OpenAlex.

Their work

Papers: 5
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 21

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 5

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yi Ba · 5 shared papers, 2014–2025 · strength 0.59
- Paper Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer. DOI 10.1007/s10637-024-01485-5 ↗
- Paper iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy DOI 10.21203/rs.3.rs-2470450/v1 ↗
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Zhi Ji · 2 shared papers, 2023–2025 · strength 0.40
- Paper Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer. DOI 10.1007/s10637-024-01485-5 ↗
- Paper iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy DOI 10.21203/rs.3.rs-2470450/v1 ↗
Rui Liu · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer. DOI 10.1007/s10637-024-01485-5 ↗
Rui Liu · 1 shared paper, 2023 · strength 0.18
- Paper iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy DOI 10.21203/rs.3.rs-2470450/v1 ↗
Duo Zuo · 1 shared paper, 2023 · strength 0.18
- Paper iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy DOI 10.21203/rs.3.rs-2470450/v1 ↗
Ning Wang · 1 shared paper, 2023 · strength 0.18
- Paper iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy DOI 10.21203/rs.3.rs-2470450/v1 ↗
Tiansuo Zhao · 1 shared paper, 2023 · strength 0.18
- Paper iRGD-modified exosomes encapsulate anti-miR-25-3p for targeted pancreatic cancer therapy DOI 10.21203/rs.3.rs-2470450/v1 ↗
Zhi‐Qiang Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Fei Zhang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
De‐Shen Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Le Zhang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Feng‐Hua Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Rui‐Hua Xu · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Wei Wang · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Yuhong Li · 1 shared paper, 2019 · strength 0.09
- Paper The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreat… DOI 10.1186/s40880-019-0367-7 ↗
Cheng Wang · 1 shared paper, 2016 · strength 0.06
- Paper Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. DOI 10.1159/000447872 ↗
Rui Liu · 1 shared paper, 2016 · strength 0.06
- Paper Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. DOI 10.1159/000447872 ↗
Yaozong Yuan · 1 shared paper, 2016 · strength 0.06
- Paper Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. DOI 10.1159/000447872 ↗
Weiyan Yao · 1 shared paper, 2016 · strength 0.06
- Paper Identification of Circulating MiR-25 as a Potential Biomarker for Pancreatic Cancer Diagnosis. DOI 10.1159/000447872 ↗
Haiyan Wang · 1 shared paper, 2014 · strength 0.04
- Paper The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with … DOI 10.3109/09537104.2013.827782 ↗
Rui Liu · 1 shared paper, 2014 · strength 0.04
- Paper The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with … DOI 10.3109/09537104.2013.827782 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.